Dunad Therapeutics
Clinical-stage biopharmaceutical company committed to developing next-generation targeted protein degradation therapies.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD41—61m (Dealroom.co estimates Mar 2021.)
Company register number 12544797
Cambridge England (HQ)
Financials
Estimates*
| GBP | 2021 | 2022 |
|---|---|---|
| Revenues | - | 7.5m |
| EBITDA | (5.1m) | (1.2m) |
| % EBITDA margin | - | (17 %) |
| Profit | (4.5m) | <1m |
| % profit margin | - | 12 % |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
£5.0m | Early VC | ||
$24.0m | Series A | ||
| Total Funding | AUD47.3m | ||
Related Content
Recent News about Dunad Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.